Publications by authors named "Sandra-Guadalupe Sanchez-Ceja"
Article Synopsis
- Methotrexate (MTX) is commonly used for treating psoriasis but can cause kidney damage, which antioxidants like vitamin C (vitC) might mitigate.
- A study using a mouse model of psoriasis explored how vitC impacts kidney toxicity from high doses of MTX, finding that while vitC can reduce kidney damage, it may worsen skin lesions and kidney injury when combined with IMQ (a psoriasis-inducing agent).
- The findings indicate that vitC could be beneficial for renal protection in psoriasis but should not be used alongside MTX in patients with existing kidney issues.
Gallic, ellagic acids and their oral combined administration induce kidney, lung, and heart injury after acute exposure in Wistar rats.
Grecia-Elena Hurtado-Nuñez Christian Cortés-Rojo Sandra-Guadalupe Sánchez-Ceja Héctor-Eduardo Martínez-Flores Rafael Salgado-Garciglia
Food Chem Toxicol
December 2022
Gallic (GA) and ellagic (EA) acids are present in foods, medicinal plants, teas, and dietary supplements. An acute toxicological study was conducted by oral administration of both compounds alone (200, 1000, and 2000 mg/kg) and combined (2000 mg/kg) and their effects on the electron transport chain (ETC) and the ROS production in kidney mitochondria further evaluated. All treatments induced a dose-dependent heart, lung, and kidney injury.
View Article and Find Full Text PDFArticle Synopsis
- - Psoriasis pain is often overlooked in clinical studies, prompting research to explore how certain anti-inflammatory agents and a compound called C48/80 affect allodynia and hyperalgesia in a mouse model of psoriasis induced by imiquimod (IMQ).
- - The study assessed pain responses in mice treated with IMQ and found that nociceptive behaviors improved with treatments like ketorolac, adalimumab, and C48/80, indicating that inflammation contributes to increased pain sensitivity.
- - Additionally, the study highlighted changes in serotonin levels in psoriasis-affected mice, suggesting the serotonergic system, particularly the 5-HT1A receptor, could be a promising target for developing new pain treatments in